http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113607711-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_38174f23f2b3b674b83436c7b2ef1d9b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N21-6402 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N21-6458 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N21-64 |
| filingDate | 2021-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_712d8d18555c7a7bbcdb7c77ff42425f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5817ed1caa432211d753439fcbbb54d0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95cbef2f984c84dc04db1c2d090f9e82 |
| publicationDate | 2021-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113607711-A |
| titleOfInvention | Method for screening anti-angiogenesis compound or evaluating anti-angiogenesis effect and toxicity effect of compound based on zebra fish platform |
| abstract | The invention relates to a method for screening an anti-angiogenesis compound or evaluating anti-angiogenesis effect and toxicity of the compound based on a zebra fish platform. The invention is based on the embryo of the transgenic zebra fish with enhanced green fluorescent protein expressed in endothelial cells, the embryo is treated by a tested compound at a proper time, an image is captured after the treatment, the length of a body segment blood vessel, the area of a blood vessel under the intestine and the area of a retinal blood vessel are measured to analyze the image, the anti-angiogenesis effect of the tested compound is finally determined, in addition, the embryo is treated by the tested compound, and the toxicity of the tested compound is evaluated by observing the survival number, the malformation number, the occurrence of pericardial edema, heart rate slowing and other toxic reactions of the embryo. The invention establishes a preclinical efficacy-toxicity model for discovering the anti-angiogenesis drug, and has the advantages of high flux and objective, accurate and comprehensive evaluation result when researching the effectiveness and safety of the drug based on the platform. |
| priorityDate | 2021-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 184.